Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis
| Autor: | Richard van Altena, Jan-Willem C. Alffenaar, Tjip S. van der Werf, Onno W. Akkerman, Sander P. van Rijn, Richard M. Anthony, Jos G. W. Kosterink, Wiel C M de Lange, Marlanka A Zuur, Bob Wilffert |
|---|---|
| Přispěvatelé: | PharmacoTherapy, -Epidemiology and -Economics, Microbes in Health and Disease (MHD), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Targeted Gynaecologic Oncology (TARGON), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Carbapenem
Imipenem INVITRO ACTIVITY Drug resistance clinical chemistry.chemical_compound 0302 clinical medicine meropenem CELL-WALL polycyclic compounds Pharmacology (medical) 0303 health sciences biology CONTAINING REGIMENS in vitro D-TRANSPEPTIDASE in vivo Infectious Diseases tuberculosis NONCLASSICAL TRANSPEPTIDASES BETA-LACTAM ANTIBIOTICS carbapenems INACTIVATION Ertapenem medicine.drug medicine.medical_specialty Tuberculosis IN-VITRO ACTIVITY Meropenem Mycobacterium tuberculosis 03 medical and health sciences ertapenem medicine MEROPENEM-CLAVULANIC ACID Intensive care medicine COMBINATION Pharmacology 030306 microbiology business.industry biochemical phenomena metabolism and nutrition medicine.disease biology.organism_classification bacterial infections and mycoses L D-TRANSPEPTIDASE Regimen 030228 respiratory system chemistry business imipenem |
| Zdroj: | Antimicrobial Agents and Chemotherapy, 63(2):ARTN e01489-18. AMER SOC MICROBIOLOGY |
| ISSN: | 1098-6596 |
| Popis: | Multi-and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of Mycobacterium tuberculosis. To better understand the potential of carbapenems for the treatment of M/XDR-TB, the aim of this review was to evaluate the literature on currently available in vitro, in vivo, and clinical data on carbapenems in the treatment of M. tuberculosis and to detect knowledge gaps, in order to target future research. In February 2018, a systematic literature search of PubMed and Web of Science was performed. Overall, the results of the studies identified in this review, which used a variety of carbapenem susceptibility tests on clinical and laboratory strains of M. tuberculosis, are consistent. In vitro, the activity of carbapenems against M. tuberculosis is increased when used in combination with clavulanate, a BLaC inhibitor. However, clavulanate is not commercially available alone, and therefore, it is impossible in practice to prescribe carbapenems in combination with clavulanate at this time. Few in vivo studies have been performed, including one prospective, two observational, and seven retrospective clinical studies to assess the effectiveness, safety, and tolerability of three different carbapenems (imipenem, meropenem, and ertapenem). We found no clear evidence at the present time to select one particular carbapenem among the different candidate compounds to design an effective M/XDR-TB regimen. Therefore, more clinical evidence and dose optimization substantiated by hollow-fiber infection studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|